Visit us at Quest Diagnostics booth #8002 | October 23-27 | Madrid, Spain
Join us at the 2026 European Society for Medical Oncology (ESMO) Congress as we share how Haystack MRD, the highly optimized evolution of the chemistry employed in the DYNAMIC study, is helping redefine the role of minimal residual disease (MRD) testing in clinical practice and oncology drug development.
Based on technology built by pioneers of cancer genomics, Haystack MRD empowers clinicians with exceptional clarity in clinical decision-making.
MRD assays are not interchangeable, and treatment decisions shouldn’t be made as if they were
At Quest Diagnostics booth #8002, you’ll learn what sets Haystack technology apart:
- Zero false positives have been observed in published clinical studies to date, giving you the confidence to act1-3
- Ultrasensitive detection (validated 95% limit of detection at 0.0006% tumor fraction) to catch the lowest levels of disease1
- Proprietary dual-strand error correction that double-checks each variant to eliminate sequencing noise
Whether you’re a clinician navigating complex treatment decisions or a biopharma leader driving trial innovation, Haystack MRD brings sensitivity, specificity, and scale to solid tumor treatment monitoring.
See our clinical data
We’re enthused to collaborate with clinical researchers who will present 2 studies at ESMO this year featuring Haystack technology:
“Circulating tumor DNA as a marker of durable remission after non-operative management of mismatch repair deficient rectal cancer“
Presentation number: 4389P
Session: Translational research and biomarkers
Session time and date: October 23, 3:15 PM-4:00 PM
This study is a follow-up to the groundbreaking immunotherapy study by Dr Cercek et al published in the New England Journal of Medicine in 2025.2 In the previous study, many patients with mismatch repair–deficient (dMMR) cancers were successfully treated with immunotherapy alone.2 In this follow-up study, 73 rectal cancer patients from the prior study underwent surveillance with Haystack MRD. In this cohort of patients treated with neoadjuvant immunotherapy, Haystack MRD identified all cases with recurrent or persistent disease, supporting its use as a surveillance tool.
“Clinical utility of ultra-sensitive ctDNA MRD monitoring in advanced NSCLC”
Presentation number: 2728eP
Session: NSCLC, metastatic
Session time and date: E-poster
This ongoing study evaluates the clinical utility of HPH MRD—a test based on Haystack MRD technology available in Germany as an in-house test manufactured by HPH—for monitoring treatment response in non–small cell lung cancer (NSCLC). Baseline testing successfully detected ctDNA in 13/13 patients assessed so far, across a wide spectrum of tumor burden levels, with baseline and longitudinal testing planned for a total of 50 patients. Preliminary results indicate correlation between ctDNA dynamics and radiomic data, clinical response, and disease progression, showing potential for ctDNA testing in prognosis and treatment monitoring in patients with advanced NSCLC.
Let’s connect in Madrid.
References
- Clark M, Prathapam R, Bramlett KS, et al. Highly accurate detection of circulating tumor DNA for monitoring minimal residual disease in solid tumors: analytical and clinical validation of the haystack MRD assay. J Mol Diagn. doi:10.1016/j.jmoldx.2026.07.006
- Cercek A, Foote MB, Rousseau B, et al. Nonoperative management of mismatch repair–deficient tumors. N Engl J Med. 2025;392(23):2297-2308. doi:10.1056/NEJMoa2404512
- Winters HD, Nguyen TJ, Suresh R, et al. Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC). J Clin Oncol. 2026;44(2_suppl):30-30. doi:10.1200/jco.2026.44.2_suppl.30
